10X Genomics

Ticker: TXG

Sector: Life Sciences Tools & Services

10X Genomics

Bryan Roberts resigns from the board of directors, effective immediately. Bryan Roberts informed the company of his decision to resign from the company. 10x Genomics to report financial results for the second quarter 2023. Analyst Consensus: Buy Stock Forecasts. Analyst consensus: Buy stock price, buy stock. 10x Genomics will report financial results for the fourth quarter and full year ended December 31, 2022 after market. CEO Serge Saxonov joins Yahoo Finance live anchor Rachell Akuffo to discuss biotechnology innovation. Stephens initiated coverage on shares of 10x Genomics with an “overweight” rating and a target price of $65.00 for the company. As of Tuesdays trading session, shares opened at $59.86 with a market cap. The Iowa NeuroBank Core has been offering 10x Genomics Visium Spatial Transcriptomics Service since 2021, and being part of the Visium Enabled Program (VEP) for additional 10X Genomics consumable discounts. 10x Genomics is seeking a Tender and Proposal Manager - Life Sciences. Pathology Assistant Income Estimation: $62,744 - $110,525 Cytotechnologist Income Estimated: $78,016 - $93,899 10X Genomics has filed 474 patents. Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation Jul 13, 2023 Mixed model-based deconvolution of cell-state abundances (MeDuSA) along a one-dimensional trajectory. 10x Genomics ( NASDAQ:TXG – Get Free Report ) last released its quarterly earnings results on Wednesday, May 3rd. CEO Serge Saxonov sold 2,000 shares of the firms stock in a transaction that occurred on Monday, May 15th. CEO has a 52-week low of $23.81.